Silo Pharma buys software assets from Parkview Consulting in stock deal
The company issued 165,000 shares to acquire technology and IP from a firm led by its crypto advisory board's lead strategic advisor.
SEC filing
Latest
Thursday, August 20
Wednesday, August 19
MediciNova signs new employment agreements with CEO Iwaki and CMO Matsuda
The August 17, 2026 agreements set new pay figures and severance terms for both executives and replace prior arrangements.
SEC filing
Korro Bio registers Phase 1/2 trial of KRRO-121 for urea cycle disorders
Jaguar Health reports Q2 2026 results, targets MVID NDA submission in Q2 2027
Jaguar said data on crofelemer in pediatric intestinal failure support an NDA package by year-end 2026, with submission planned for the second quarter of 2027.
SEC filing
Aer Therapeutics discloses $3 million securities offering in SEC Form D filing
The Delaware biotech, based in Research Triangle Park, reported selling out a $3,000,000 offering to seven investors under a Rule 506(b) exemption.
SEC filing
Enanta posts results for Phase 2b EDP-938 RSV trial in high-risk adults
Nasus Pharma CFO Eyal Rubin to resign, interim successor named
The company said Rubin will leave to pursue an opportunity outside life sciences, with Director of Finance Oren Elmaliach stepping in as interim CFO.
SEC filing
Revelation Biosciences grants restricted stock to CEO and CFO tied to market cap goals
The awards to James Rolke and Chester S. Zygmont, III vest in tranches as the company's market capitalization hits set thresholds or fixed anniversary dates pass.
SEC filing
Cybin files two Form D notices for equity awards to executives and directors
The Toronto-based company registered separate exempt offerings covering restricted share units and performance share units, both dated August 18, 2026.
SEC filing (2)
Longeveron names Nirav Jhaveri as chief financial officer
The clinical-stage biotech said Jhaveri succeeds Marie Washburn, who returns to her prior role as corporate controller, effective August 17, 2026.
SEC filing
Crescel LLC files Form D for $2 million securities offering
The Florida biotechnology company reported $1.1 million already raised from eight investors as of a first sale date of August 18, 2026.
SEC filing
Intercure files Form D covering equity issued for Botanico acquisition
Intercure Ltd. registered a new securities offering tied to a share and warrant transaction related to its acquisition of ISHI (Botanico Ltd.), with a first sale date of June 15, 2026.
SEC filing
Astellas registers Phase 1/2 gene therapy trial for ASP2767 in glaucoma optic nerve damage
Axsome registers Phase 3 long-term safety study of Sunosi in pediatric ADHD
Exelixis registers Phase 1 pediatric trial of zanzalintinib in solid tumors
CalciMedica stockholders back plan increase, reverse split, and warrant issuances at annual meeting
The August 19, 2026 vote covered eight proposals, including a 7,500,000-share bump to the equity incentive plan and a reverse stock split ratio of up to 1-for-10.
SEC filing
Kiora licenses South Korean rights to KIO-301 to Chong Kun Dang
The deal gives Kiora a $1 million upfront payment plus potential milestones and royalties as CKD takes on ophthalmic development in South Korea.
SEC filing
Boehringer adds survodutide bioequivalence trial alongside BI 3000202 transporter study
Cocrystal Pharma posts Phase 1 results for CDI-988, an oral SARS-CoV-2 antiviral candidate
argenx registers Phase 2 trial of ARGX-121 in IgA nephropathy
PDS Biotechnology CFO Lars Boesgaard to resign, interim replacements named
The company's controller and CEO will take on interim finance officer roles effective September 12, 2026, following Boesgaard's departure.
SEC filing
Telix reports 22% H1 2026 revenue growth, guides to upper end of FY targets
Telix posted $477M in first-half revenue and net profit of $38M, while advancing five late-stage clinical programs and a Regeneron collaboration.
SEC filing
Tuesday, August 18
Amylyx reports positive Phase 3 results for avexitide in post-bariatric hypoglycemia
The LUCIDITY trial hit its primary endpoint with a 55% reduction in hypoglycemic events, and Amylyx plans to file for FDA approval by year-end.
SEC filing (2)
Oncolytics gets FDA feedback on pivotal path for pelareorep in colorectal cancer
The FDA's written response addresses a possible accelerated approval route for REO 033's Part B expansion in second-line RAS-mutant MSS metastatic colorectal cancer.
SEC filing
BioMarin to acquire Alesta Therapeutics for its oral HPP drug candidate ALE1
BioMarin will pay $275 million upfront plus up to $215 million in milestones for ALE1, a small molecule being tested as a potential first oral therapy for hypophosphatasia.
SEC filing
Helus Pharma names Intra-Cellular veterans to leadership and advisory roles
Cybin's commercial unit Helus Pharma added a Chief People Officer and a Scientific Advisory Board member, both formerly of Intra-Cellular Therapies.
SEC filing (2)
Apollomics closes $10 million private placement, insiders take part
The Nasdaq-listed oncology company sold Class A shares to accredited investors, with its CEO, CFO, and an affiliate of its COO among the buyers.
SEC filing (2)
Entera Bio names Riccardo Camisasca as chief medical officer
The appointment, effective immediately, comes ahead of the company's planned Phase 3 start for its lead osteoporosis candidate EB613.
SEC filing
Liminatus Pharma sets 1-for-50 reverse stock split to regain Nasdaq compliance
The split takes effect August 20, 2026, part of an effort to satisfy Nasdaq's minimum bid price rule after months of listing deficiency notices.
SEC filing
Immuron outlines pipeline partnering push at Emerging Growth Conference
CEO Steven Lydeamore's August 19, 2026 presentation detailed FY26 sales, cash position, and plans to license out IMM-124E and IMM-529.
SEC filing (2)
Tonix Pharmaceuticals names CEO Seth Lederman as interim chief medical officer
The board added the interim CMO role to Lederman's existing duties as president, CEO, and chairman, effective August 18, 2026.
SEC filing
Turn Therapeutics discloses GEM's cashless warrant exercise for 579,664 shares
The company issued the shares under a warrant tied to its 2025 share purchase agreement with GEM, filed August 18, 2026.
SEC filing
Chong Kun Dang collaborator on new Korean registry study of SGLT2, GLP-1 drugs in T2DM heart health
Agenus subsidiary amends Ocean 1181 loan, extends maturity to 2029
Agenus West and Agenus Inc. restructured a $24.75 million promissory note with lender Ocean 1181 LLC, pushing the maturity date back roughly three years.
SEC filing
SciSparc subsidiary NeuroThera raises C$5.4 million in private placement financing
SciSparc invested C$2.7 million in the round, holding roughly 44.6% of NeuroThera afterward with its stake valued at about C$30 million.
SEC filing
Halozyme adds Dannielle Appelhans to board of directors
Halozyme Therapeutics disclosed the August 14, 2026 board appointment in an 8-K filed with the SEC.
SEC filing
Legend Biotech seeks shareholder approval to add 19.1 million shares to RSU plan
The proxy for Legend Biotech's September 24, 2026 annual meeting asks holders to expand the equity plan and re-elect four Class III directors.
SEC filing
Amgen terminates Crohn's disease collaboration with TScan Therapeutics
Amgen notified TScan on August 12, 2026 that it is exiting their research agreement, effective November 10, 2026.
SEC filing
Cocrystal Pharma adds Carol Brosgart, MD to board of directors
The antiviral biotech named the physician-scientist and veteran biopharma board member to its board effective August 12, 2026.
SEC filing (2)
Ocugen registers Phase 3 trial of OCU410 gene therapy for geographic atrophy in dry AMD
BeOne registers pediatric trial of sonrotoclax in relapsed AML and B-cell ALL
HUTCHMED discloses insolvency of company linked to its chairman
HUTCHMED said a medical device firm where Chairman Dan Eldar previously served as director has entered insolvency proceedings in Israel.
SEC filing
Roche's glofitamab Phase 2 trial in untreated DLBCL posts results after primary completion
Cypherpunk Technologies acquires Zcash mining fleet from Winklevoss Capital
The $33.33 million equity-based deal, announced August 18, 2026, gives Cypherpunk a mining operation representing about 18% of the Zcash network's hashrate.
SEC filing
Kardigan registers Phase 3 open-label extension for danicamtiv in genetic DCM
Prenetics reports IM8 revenue up 288% in Q2 2026, raises full-year guidance
The company said July was its strongest month yet for IM8 and its first month of positive consolidated adjusted free cash flow.
SEC filing
Kite's ZUMA-2 Cohort 3 trial in BTKi-naive mantle cell lymphoma completes, results posted
Glenmark wins FDA approvals for fluticasone nasal spray, rosuvastatin label update
Monday, August 17
Dermata Therapeutics announces $3.4 million private placement
The San Diego dermatology company said insiders including its CEO and CFO are participating in the at-the-market priced deal, set to close August 18, 2026.
SEC filing